Exenatide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Exenatide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
363
Registered trials
278
Result records
9
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Exenatide can convert its Synthetic peptide profile and GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Exenatide (query alias: exenatide) |
|---|---|
| Modality / target | Synthetic peptide; GLP-1R; GLP-1R agonists |
| Highest global status | Approved |
| Originator | Eli Lilly & Co., Amylin Pharmaceuticals, Inc. |
| Active developers | AstraZeneca AB, AstraZeneca KK, Eli Lilly Nederland BV |
The MCP disease footprint includes Diabetes Mellitus, Type 2, Parkinson Disease, Diabetes Mellitus. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600116060 | Early Phase 1 | Pending | 9 | Safety and Tolerability Endpoints: Include AE/SAE, laboratory tests (including hematology, blood biochemistry, lipase, amylase, urinalysis, fasting plasma glucose, etc.), 12-lead ECG (including PR interval, QRS duration, QTcF interval, etc.), physical examination (including skin, mucous membranes, lymph nodes, head and neck, chest, abdomen, and other areas), and vital signs (blood pressure, pulse rate, body temperature, respiration). |
| NCT06252623 | Phase 1 | Withdrawn | Not disclosed | Proportion of up to 10 active cocaine doses |
| ChiCTR2300074467 | Not disclosed | Not yet recruiting | 490 | detection rate |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Do GLP-1s SCAR? A FAERS Disproportionality Analysis of Severe Cutaneous Adverse Reactions to GLP-1 Receptor Agonists
Not Applicable; n=917; evaluation: Negative. Reported fields: -; -; Disability = 10.0 %
GLP-1 receptor agonists-associated skin events: identifying the most common culprits and reactions
Not Applicable; n=15780; evaluation: Positive. Reported fields: AE = common AEs were rash (26.1%), pruritus (22.1%), alopecia (14.8%), hyperhidrosis (14.6%), and urticaria (3.5%). % ; AE = common AEs were rash (26.1%), pruritus (22.1%), alopecia (14.8%), hyperhidrosis (14.6%), and urticaria (3.5%). % ; AE = 14.8 %
A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults
Phase 4; n=not disclosed; evaluation: Positive. Reported fields: Adverse Event: gastrointestinal symptoms = The most common side effects in the exenatide group were gastrointestinal symptoms ; Adverse Event: gastrointestinal symptoms = The most common side effects in the exenatide group were gastrointestinal symptoms
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Exenatide addresses Diabetes Mellitus, Type 2, Parkinson Disease, Diabetes Mellitus. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 9 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-08-28 | i2o Therapeutics Names Kurt Graves Chairman and CEO, Announces Corporate Updates | Not disclosed | Financial terms not disclosed |
| 2023-02-28 | 三生制药与阿斯利康签订的独家许可协议及其下许可产品的商业化将于2023年12月31日终止 | Approved | US$50.0M upfront; US$50.0M milestones |
| 2021-09-27 | Peptron will distribute Invex's Presendin for IIH in South Korea. | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Preparation method of exenatide sustained release microspheres”. The milestone feed surfaced a patent-application signal described as “Long acting glucagon like polypeptide-1 (GLP-1) receptor agonists and methods of use”. The milestone feed surfaced a patent-application signal described as “Exenatide enteric capsule and preparation method thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
